

CERVICAL CANCER SCREENING

VOLUME 18

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Interventions, which met remotely, 12–16 October 2020

LYON, FRANCE - 2022

IARC HANDBOOKS OF
CANCER PREVENTION

LIST OF PARTICIPANTS

Members ¹

Silvina Arrossi

Center for the Study of State and
Society/National Council for Scientific
and Technical Research (CEDES/
CONICET)
Buenos Aires
Argentina

Johannes Berkhof (Subgroup Chair, Preventive and Adverse Effects of HPV Tests)

Department of Epidemiology and Data
Science
Amsterdam University Medical Centers
Amsterdam
The Netherlands

Karima Bendahhou

Casablanca Cancer Registry
Centre Mohammed VI pour le traitement des
cancers
Casablanca
Morocco

Julia Brotherton ² (Subgroup Chair, Preventive and Adverse Effects of Visual and Cytological Methods)

VCS Foundation Ltd
Melbourne
Australia

¹ Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only. Invited Specialists do not serve as Meeting Chair or Subgroup Chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations. Each participant was asked to declare potentially relevant research, employment, and financial interests that are current or that have occurred during the past 4 years. Minimal interests are not disclosed here and include stock valued at no more than US\$ 1000 overall, grants that provide no more than 5% of the research budget of the expert's organization and that do not support the expert's research or position, and consulting or speaking on matters not before a court or government agency that does not exceed 2% of total professional time or compensation. All other non-publicly funded grants that support the expert's research or position and all consulting or speaking on behalf of an interested party on matters before a court or government agency are disclosed as potentially significant conflicts of interests.

² Julia Brotherton reports that her unit at VCS Population Health benefits from research funding and equipment from Roche, Seegene, Cepheid, and Becton Dickinson.

Karen Canfell

The Daffodil Centre, The University of
Sydney, a joint venture with Cancer
Council NSW
Woolloomooloo
Australia

Z. Mike Chirenje

University of Zimbabwe College of Health
Sciences - Clinical Trials Research Centre
(UZCHS-CTRC)
Harare
Zimbabwe

Michael H. Chung

Division of Infectious Diseases
Department of Medicine
Emory University
Atlanta, GA
USA

Marta del Pino

Gynecologic Oncology Unit
Clinical Institute of Gynecology, Obstetrics
and Neonatology (ICGON)
Hospital Clínic de Barcelona
Institut d'Investigacions Biomèdiques August
Pi i Sunyer (IDIBAPS)
University of Barcelona
Barcelona
Spain

Silvia de Sanjosé

Reproductive Health Global Program
PATH
Seattle, WA
USA

*Miriam Elfström*³

Center for Cervical Cancer Prevention
Karolinska University Hospital
Department of Laboratory Medicine
Karolinska Institutet
Huddinge
Sweden

*Eduardo Franco*⁴

Division of Cancer Epidemiology
McGill University
Montreal, Quebec
Canada

*Paolo Giorgi-Rossi (Subgroup Vice-Chair,
Preventive and Adverse Effects of Visual
and Cytological Methods)*

Epidemiology Unit
Azienda Unità Sanitaria Locale – IRCCS
di Reggio Emilia
Reggio Emilia
Italy

Chisato Hamashima

Teikyo University
and
National Cancer Center of Japan
Tokyo
Japan

³ Miriam Elfström reports that her unit at Karolinska Institutet benefited from non-monetary research support from Sanofi Pasteur MSD SNC.

⁴ Eduardo Franco reports being editor in-chief of the journals *Preventive Medicine* and *Preventive Medicine Reports*.

Françoise F. Hamers

French National Public Health Agency
Saint-Maurice
France

Suleeporn Sangrajrang

National Cancer Institute
Bangkok
Thailand

C. Simon Herrington

Institute of Genetics and Molecular Medicine
(IGMM)
Division of Pathology
University of Edinburgh
Edinburgh
United Kingdom

Rengaswamy Sankaranarayanan

RTI International India
New Delhi
India

Rachel Kupets (Subgroup Chair, Cervical Cancer and Screening Practices)

Division of Gynecologic Oncology
University of Toronto
Ontario Cervical Cancer Screening Program
Cancer Prevention, Cancer Care Ontario
Toronto, Ontario
Canada

Mona Saraiya

Centers for Disease Control and Prevention
Atlanta, GA
USA

Anne Mackie (Meeting Co-Chair)

Public Health England Screening
London
United Kingdom

Mark Schiffman⁵

Clinical Epidemiology Unit
Clinical Genetics Branch
Division of Cancer Epidemiology and
Genetics
National Cancer Institute
Rockville, MD
USA

Raúl Murillo

Centro Javeriano de Oncología
Hospital Universitario San Ignacio
Facultad de Medicina
Pontificia Universidad Javeriana
Bogotá
Colombia

Robert Smith (Subgroup Chair, Differential-Risk Populations and Screen-and-Treat)

American Cancer Society
Atlanta, GA
USA

⁵Mark Schiffman reports that his unit at the National Cancer Institute benefited from equipment and supplies from Qiagen and MobileODT.

Nicolas Wentzensen (Meeting Co-Chair)

Clinical Epidemiology Unit
Clinical Genetics Branch
Division of Cancer Epidemiology and
Genetics
National Cancer Institute
Rockville, MD
USA

Representative

Carolina Wiesner

Colombian National Cancer Institute
Bogotá
Colombia

Fanghui Zhao

Department of Cancer Epidemiology
National Cancer Center and Cancer Hospital
Chinese Academy of Medical Sciences
Beijing
China

Observer⁸

Jae-Weon Kim

Department of Obstetrics and Gynecology
Seoul National University College of
Medicine
Seoul
Republic of Korea

Invited Specialists

*Marc Arbyn*⁶

Sciensano
Brussels
Belgium

*Walter Prendiville*⁷

Senior Visiting Scientist
International Agency for Research on Cancer
Lyon
France

IARC/WHO Secretariat

Maribel Almonte, Head, Prevention and
Implementation Group
Armando Baena, Prevention and
Implementation Group
Partha Basu, Head, Screening Group
Iacopo Baussano, Infections and Cancer
Epidemiology Group

⁶ Marc Arbyn reports that his unit at Sciensano benefits from non-monetary support from manufacturers of human papillomavirus (HPV) assays and devices.

⁷ Walter Prendiville reports holding stocks in NSV, receiving consultancy fees from Koru Auckland, and receiving royalties from Utah Medical Products, Inc. for patent #5951550.

⁸ Each Observer agreed to respect the Guidelines for Observers at *IARC Handbooks* meetings. Observers did not serve as Meeting Chair or Subgroup Chair, draft or revise any part of the *Handbook*, or participate in the evaluations. They also agreed not to contact participants before or after the meeting, not to lobby them at any time, not to send them written materials, and not to offer them meals or other favours. IARC asked and reminded Working Group Members to report any contact or attempt to influence that they may have encountered, either before or during the meeting.

Véronique Bouvard, IARC Handbooks Group (*Co-Responsible Officer, Co-Rapporteur*)

Nathalie Broutet, WHO headquarters
Citadel Cabasag, Section of Cancer Surveillance

Gary Clifford, Head, Infections and Cancer Epidemiology Group

Ian Cree, Head, Section of Evidence Synthesis and Classification

Hugo De Vuyst, Prevention and Implementation Group

Carolina Espina Garcia, Section of Environment and Radiation

Elena Fidarova, WHO headquarters

Mathilde Forestier, Visiting Scientist, Prevention and Implementation Group

John Grove, WHO headquarters

Isabelle Heard, Visiting Scientist, Prevention and Implementation Group

Blanca Iciar Indave, WHO Classification of Tumours Group (*Co-Rapporteur*)

Béatrice Lauby-Secretan, Head, IARC Handbooks Group (*Co-Responsible Officer, Co-Rapporteur*)

Isabel Mosquera-Metcalf, Screening Group (*Co-Rapporteur*)

Karen Müller, Communications Group (*Editor*)

Tatiana Ramirez, Prevention and Implementation Group

Mariluz Rol, Prevention and Implementation Group

Guglielmo Ronco, Visiting Scientist, Infections and Cancer Epidemiology Group

Nancy Santesso, WHO headquarters

Catherine Sauvaget, Screening Group

Farida Selmouni, Screening Group

Vitaly Smelov, Prevention and Implementation Group [unable to attend]

Salvatore Vaccarella, Section of Cancer Surveillance [unable to attend]

Patricia Villain, Screening Group

Administrative Assistance

Marieke Dusenbergh

Michel Javin

Jennifer Nicholson

Production Team

Fiona Gould

Niree Kraushaar

Solène Quennehen

Scientific Assistance

Armando Baena, IARC

Mónica Ballesteros Silva

Dominika Bhatia

Helen Kelly

Tatiana Ramirez, IARC

Remila Rezhake

Joan Valls Marsal, IARC

Post-Meeting Assistance

Harriet Stewart-Jones (*Scientific Editor*)